Functional Brands Adds NAD+ Therapy Enhancing GLP-1 and Peptide Integration

MEHAMEHA

Functional Brands Inc. has added clinically supervised NAD+ therapy to its Tru2u.health platform, complementing its existing GLP-1 weight management, peptide protocols, and telehealth services. The therapy targets cellular energy production, DNA repair, and metabolic function, potentially driving increased subscriber engagement and revenue synergies.

1. Expansion of Digital Health Platform

Functional Brands has integrated NAD+ therapy into Tru2u.health, expanding its digital health offerings beyond GLP-1 weight management, peptides, and telehealth support to include coenzyme therapies targeting cellular health.

2. NAD+ Therapeutic Benefits

NAD+ is essential for ATP production, DNA repair, sirtuin activation and metabolic regulation, addressing age-related declines and supporting cognitive and physical performance.

3. Synergies with Existing Programs

NAD+ complements GLP-1 weight management by enhancing insulin sensitivity and fat oxidation, and augments peptide protocols by improving mitochondrial function and muscle recovery.

4. Delivery and Clinical Oversight

Board-certified providers on Tru2u.health will personalize NAD+ dosing, ensure safe administration via telehealth consultations, and integrate therapy into patients' broader wellness plans.

Sources

N